Expression analysis of angiogenic growth factors and biological axis CXCL12/CXCR4 axis in idiopathic pulmonary fibrosis

Connective Tissue Research

Volumn 51, Issue 1, 2010, Pages 71-80

  Antoniou, Katerina M ^a   Soufla, Giannoula ^b   Lymbouridou, Rena ^b   Economidou, Foteini ^a   Lasithiotaki, Ismini ^a   Manousakis, Manolis ^b   Drositis, Ioannis ^b   Spandidos, Demetrios A ^b   Siafakas, Nikolaos M ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Angiogenesis; Chemokines; IPF; Vascular remodeling

Indexed keywords

ANGIOGENIC FACTOR; CHEMOKINE RECEPTOR CXCR4; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; RNA; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; LUNG PARENCHYMA; MALE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; THORAX SURGERY; TOTAL LUNG CAPACITY; TRANSCRIPTION REGULATION;

ANGIOGENIC PROTEINS; BIOLOGICAL MARKERS; CHEMOKINE CXCL12; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INSULIN-LIKE GROWTH FACTOR I; LUNG; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75149197267     PISSN: 03008207     EISSN: 16078438     Source Type: Journal    
DOI: 10.3109/03008200903056150     Document Type: Article

References (45)

1. Katzenstein, A.L. and Myers, J.L. (1998). Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care. Med., 157, 1301-1315.
2. Antoniou, K.M., Pataka, A., Bouros, D., and Siafakas, N.M. (2007). Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther., 20, 453-461.
3. Bouros, D. and Antoniou, K.M. (2005). Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur. Respir. J., 26, 693-702.
4. American Thoracic Society/European Respiratory Society. (2002). Internationalmultidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care. Med., 165, 277-304.
5. Selman, M., King, T.E., and Pardo, A. (2001). Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med., 134, 136-151.
6. Li, B., Sharpe, E.E., Maupin, A.B., Teleron, A.A., Pyle, A.L., Carmeliet, P., and Young, P.P. (2006). VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J., 20, 1495-1497.
7. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82, 4-6.
8. Carmeliet, P. and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257.
9. Hoshino, M., Nakamura, Y., and Hamid, Q.A. (2001). Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J. Allergy Clin. Immunol., 107, 1034-1038.
10. Siafakas, N.M., Antoniou, K.M., and Tzortzaki, E.G. (2007). Role of angiogenesis and vascular remodeling in chronic obstructive pulmonary disease. Int. J. Chron Obstruct. Pulmon. Dis., 2, 453-462.
11. Tzouvelekis, A., Anevlavis, S., and Bouros, D. (2006). Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? Respir. Res., 7, 82.
12. Renzoni, E.A. (2004). Neovascularization in idiopathic pulmonary fibrosis: too much or too little? Am. J. Respir. Crit. Care. Med., 169, 1179-1180.
13. Keane, M.P. (2004). Angiogenesis and pulmonary fibrosis. Feast or famine? Editorial. Am. J. Respir. Crit. Care Med., 170, 207.
14. Krein, P.M. andWinston, B.W. (2002). Roles for insulin-like growth factor I and transforming growth factor-beta in fibrotic lung disease. Chest, 122, 289S-293S.
15. Lappi-Blanco, E., Soini, Y., Kinnula, V., and Paakko, P. (2002). VEGF and bFGF are highly expressed in intraluminal fibromyxoid lesions in bronchiolitis obliterans organizing pneumonia. J. Pathol., 196, 220-227.
16. Coker, R.K., Laurent, G.J., Shahzeidi, S., Lympany, P.A., du Bois, R.M., Jeffery, P.K., andMcAnulty, R.J. (1997). Transforming growth factors-beta 1, -beta 2, and -beta 3 stimulate fibroblast procollagen production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. Am. J. Pathol., 150, 981-991.
17. Tang, B., Vu, M., Booker, T., Santner, S.J., Miller, F.R., Anver, M.R., and Wakefield, L.M. (2003). TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J. Clin. Invest., 112, 1116-1124.
18. Wakefield, L.M. and Roberts, A.B. (2002). TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev., 12, 22-29.
19. Keane, M.P., Arenberg, D.A., Lynch, J.P. 3rd, Whyte, R.I., Iannettoni, M.D., Burdick, M.D., Wilke, C.A., Morris, S.B., Glass, M.C., DiGiovine, B., Kunkel, S.L., and Strieter, R.M. (1997). The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J. Immunol., 159, 1437-1443.
20. Belperio, J.A., Keane, M.P., Arenberg, D.A., Addison, C.L., Ehlert, J.E., Burdick, M.D., and Strieter, R.M. (2000). CXC chemokines in angiogenesis. J. Leukoc. Biol., 68, 1-8.
21. Strieter, R. M., Starko, K. M., Enelow, R. I., Noth, I., and Valentine, V. G. (2004). Idiopathic pulmonary fibrosis. Biomarkers study group effects of interferon gamma-1b on biomarker expression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 170, 133-140.
22. Bouros, D., Antoniou, K. M., and Siafakas, N. M. (2005). Does interferon gamma-1b therapy improve survival in IPF via an angiogenetic pathways? Chest (personal communication
23. Antoniou, K.M., Alexandrakis, M.G., Sfiridaki, K., Tsiligianni, I., Perisinakis, K., Tzortzaki, E.G., Siafakas, N.M., and Bouros, D.E. (2004). Th1 cytokine pattern (IL-12 and IL-18) in BALF before and after treatment with interferon gamma-1b (IFN-g-1b) or colchicine in patients with in idiopathic pulmonary fibrosis (IPF/UIP). Sarcoidosis Vasc. Diffuse Lung. Dis., 21, 105-110.
24. Lama, V.N. and Phan, S.H. (2006). The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. Proc. Am. Thorac. Soc., 3, 373-376.
25. Soulitzis, N., Karyotis, I., Delakas, D., and Spandidos, D.A. (2006). Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int. J. Oncol., 29, 305-314.
26. Turner-Warwick,M. (1963). Precapillary systemic pulmonary anastomoses. Thorax., 18, 225-237.
27. Cosgrove, G.P., Brown, K.K., Schiemann, W.P., Serls, A.E., Parr, J.E., Geraci, M.W., Schwarz, M.I., Cool, C.D., and Worthen, G.S. (2004). Pigment epitheliumderived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am. J. Respir. Crit. Care Med., 170, 242-251.
28. Renzoni, E.A., Walsh, D.A., Salmon, M., Wells, A.U., Sestini, P., Nicholson, A.G, Veeraraghavan, S., Bishop A.E., Romanska, H.M., Pantelidis, P., Black, C.M., and Du Bois, R.M. (2003). Interstitial vascularity in fibrosing alveolitis. Am. J. Respir. Crit. Care Med., 167, 438-443.
29. Keane, M.P., Belperio, J.A., Burdick, M.D., Lynch, J.P., Fishbein, M.C., and Strieter, R.M. (2001). ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med., 164, 2239-2242.
30. Ebina, M., Shimizukawa, M., Shibata, N., et al. (2004). Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med., 169, 1203-1208.
31. Antoniou, K.M., Tzouvelekis, A., Alexandrakis, M.G., Sfiridaki, K., Tsiligianni, I., Rachiotis, G., Tzanakis, N., Bouros, D., Milic-Emili, J., and Siafakas, N.M. (2006). Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest, 130, 982-988.
32. Blau, H.M. and Banfi, A. (2001). The well-tempered vessel. Nat. Med., 7, 532-534.
33. Semenza, G.L. (2001). Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to dance. J. Clin. Invest., 174, 71-76.
34. Willis, B.C., duBois, R.M., and Borok, Z. (2006). Epithelial origin of myofibroblasts during fibrosis in the lung. Proc. Am. Thorac. Soc., 3, 377-382. Review.
35. Selman, M., Pardo, A., and Kaminski, N. (2008). Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med., 5, e62.
36. Königshoff, M. and Eickelberg, O. (2009 Mar 27). WNT Signaling in lung disease: a failure or a regeneration signal? Am. J. Respir. Cell Mol. Biol., [Epub ahead of print].
37. Frankel, S.K., Moats-Staats, B.M., Cool, C.D., Wynes, M.W., Stiles, A.D., and Riches, D.W. (2005). Human insulin-like growth factor-IA expression in transgenic mice promotes adenomatous hyperplasia but not pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol., 288, L805-L812.
38. Bloor, C.A., Knight, R.A., Kedia, R.K., Spiteri, M.A., and Allen, J.T. (2001 Jul 15). Differential mRNA expression of insulin-like growth factor-1splice variants in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am. J. Respir. Crit. Care. Med., 164, 265-272.
39. Krein, P. M., Sabatini, P. J., Tinmouth, W., Green, F. H., and Winston, B. W. (2003). Localization of insulin-like growth factor-I in lung tissues of patients with fibroproliferative acute respiratory distress syndrome. Am. J. Respir. Crit. Care. Med., 167, 83.
40. Aston, C., Jagirdar, J., Lee, T. C., Hur, T., Hintz, R. L., and Rom, W. N. (1995). Enhanced insulin-like growth factor molecules in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med., 151, 1597.
41. Inoue, Y., King, T. E. Jr., Tinkle, S. S., Dockstader, K., and Newman, L. S. (1996). Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am. J. Pathol., 149, 2037.
42. Ishii,Y., Fujimoto, S., and Fukuda, T. (2006).Gefitinib prevents bleomycininduced lung fibrosis inmice. Am. J. Respir. Crit. Care.Med., 174, 550-556.
43. Strieter, R.M., Gomperts, B.N., and Keane, M.P. (2007). The role of CXC chemokines in pulmonary fibrosis. J. Clin. Invest., 117, 549-556.
44. Mehrad, B., Burdick, M.D., Zisman, D.A., Keane, M.P., Belperio, J.A., and Strieter, R.M. (2007). Circulating peripheral blood fibrocytes in human fibrotic interstitial lung disease. Biochem. Biophys. Res. Commun., 353, 104-108.
45. Phillips, R.J., Burdick, M.D., Hong, K., Lutz, M.A., Murray, L.A., Xue, Y.Y., Belperio, J.A., Keane, M.P., and Strieter, R.M. (2004). Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest., 114, 438-446.